🚀 VC round data is live in beta, check it out!
AcuCort Valuation Multiples
Discover revenue and EBITDA valuation multiples for AcuCort and similar public comparables like Biotechnology Assets, Alligator Bioscience, Active Biotech, Aelis Farma and more.
AcuCort Overview
About AcuCort
AcuCort AB is an innovative biotechnology company that identifies, develops and commercializes smart drugs that meet the patient’s needs for a user-friendly and effective treatment.
Founded
2006
HQ
Employees
2
Website
Sectors
Financials (LTM)
EV
$18M
AcuCort Financials
AcuCort reported last 12-month revenue of $227K and negative EBITDA of ($2M).
In the same LTM period, AcuCort generated $175K in gross profit, ($2M) in EBITDA losses, and had net loss of ($3M).
Revenue (LTM)
AcuCort P&L
In the most recent fiscal year, AcuCort reported revenue of $77K and EBITDA of ($2M).
AcuCort expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $227K | XXX | $77K | XXX | XXX | XXX |
| Gross Profit | $175K | XXX | $727K | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 940% | XXX | XXX | XXX |
| EBITDA | ($2M) | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | (984%) | XXX | (2495%) | XXX | XXX | XXX |
| EBIT Margin | (1369%) | XXX | (3725%) | XXX | XXX | XXX |
| Net Profit | ($3M) | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | (1359%) | XXX | (3682%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AcuCort Stock Performance
AcuCort has current market cap of $21M, and enterprise value of $18M.
Market Cap Evolution
AcuCort's stock price is $0.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18M | $21M | -0.5% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAcuCort Valuation Multiples
AcuCort trades at 80.5x EV/Revenue multiple, and (8.2x) EV/EBITDA.
EV / Revenue (LTM)
AcuCort Financial Valuation Multiples
As of April 18, 2026, AcuCort has market cap of $21M and EV of $18M.
Equity research analysts estimate AcuCort's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AcuCort has a P/E ratio of (6.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21M | XXX | $21M | XXX | XXX | XXX |
| EV (current) | $18M | XXX | $18M | XXX | XXX | XXX |
| EV/Revenue | 80.5x | XXX | 235.6x | XXX | XXX | XXX |
| EV/EBITDA | (8.2x) | XXX | (9.4x) | XXX | XXX | XXX |
| EV/EBIT | (5.9x) | XXX | (6.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 104.4x | XXX | 25.1x | XXX | XXX | XXX |
| P/E | (6.9x) | XXX | (7.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AcuCort Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AcuCort Margins & Growth Rates
AcuCort's revenue in the last 12 month grew by 438%.
AcuCort's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.
AcuCort's rule of 40 is 210% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AcuCort's rule of X is 1227% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
AcuCort Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 438% | XXX | 651% | XXX | XXX | XXX |
| EBITDA Margin | (984%) | XXX | (2495%) | XXX | XXX | XXX |
| EBITDA Growth | (1%) | XXX | 41% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 210% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 1227% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 4665% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
AcuCort Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AcuCort | XXX | XXX | XXX | XXX | XXX | XXX |
| Biotechnology Assets | XXX | XXX | XXX | XXX | XXX | XXX |
| Alligator Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Active Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Aelis Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Diamyd Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AcuCort M&A Activity
AcuCort acquired XXX companies to date.
Last acquisition by AcuCort was on XXXXXXXX, XXXXX. AcuCort acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by AcuCort
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAcuCort Investment Activity
AcuCort invested in XXX companies to date.
AcuCort made its latest investment on XXXXXXXX, XXXXX. AcuCort invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by AcuCort
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AcuCort
| When was AcuCort founded? | AcuCort was founded in 2006. |
| Where is AcuCort headquartered? | AcuCort is headquartered in Sweden. |
| How many employees does AcuCort have? | As of today, AcuCort has over 2 employees. |
| Is AcuCort publicly listed? | Yes, AcuCort is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of AcuCort? | AcuCort trades under ACUC ticker. |
| When did AcuCort go public? | AcuCort went public in 2017. |
| Who are competitors of AcuCort? | AcuCort main competitors are Biotechnology Assets, Alligator Bioscience, Active Biotech, Aelis Farma. |
| What is the current market cap of AcuCort? | AcuCort's current market cap is $21M. |
| What is the current revenue of AcuCort? | AcuCort's last 12 months revenue is $227K. |
| What is the current revenue growth of AcuCort? | AcuCort revenue growth (NTM/LTM) is 438%. |
| What is the current EV/Revenue multiple of AcuCort? | Current revenue multiple of AcuCort is 80.5x. |
| Is AcuCort profitable? | No, AcuCort is not profitable. |
| What is the current EBITDA of AcuCort? | AcuCort has negative EBITDA and is not profitable. |
| What is AcuCort's EBITDA margin? | AcuCort's last 12 months EBITDA margin is (984%). |
| What is the current EV/EBITDA multiple of AcuCort? | Current EBITDA multiple of AcuCort is (8.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.